Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 18 2023 - 4:01PM
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical
company developing a new class of complement medicines for patients
with classical complement-mediated autoimmune, neurodegenerative
and ophthalmic disorders, today announced that it has granted
inducement to two new non-executive employees under the terms of
the 2022 Employment Inducement Award Plan. The equity awards were
approved on October 17, 2023, in accordance with Nasdaq Listing
Rule 5635(c)(4).
In the aggregate, the new non-executive
employees received options to purchase 75,600 shares of Annexon
common stock. The options carry a ten-year term and an exercise
price per share equal to $1.77, which was the closing price of
Annexon’s common stock on October 17, 2023, the date of grant, and
vest over 4 years, with 25% of the shares underlying the options
vesting on the first anniversary of the grant date and an
additional 1/48th of the shares vesting monthly thereafter, subject
to continued service through the applicable vesting dates.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a
clinical-stage biopharmaceutical company utilizing a distinctive
scientific approach to stop the initiator of classical
complement-mediated inflammation, C1q, before it starts. As the
only company solely focused on shutting down C1q, Annexon is
developing a purposeful pipeline of investigational medicines
designed to provide meaningful benefits across multiple diseases of
the body, brain and eye. With proof-of concept data in both
Guillain-Barré syndrome and geographic atrophy, Annexon is
rigorously advancing mid-to late-stage clinical trials to bring
first-of-their kind therapies to millions of people living with
devastating inflammatory-related diseases. To learn more visit
annexonbio.com.
Investor Contact:
Chelcie ListerTHRUST Strategic
Communicationsmonique@thrustsc.com
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Apr 2024 to May 2024
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From May 2023 to May 2024